Showing results (221-230 of 266) with videos related to

Sort By:
Pageof 27
Clinical and Experimental Dermatology|February 3, 2025
Efficacy and Drug Survival of Tralokinumab in Severe Atopic Dermatitis: An 18-Month Multicenter ExperienceFrancesca Barei, Paolo Calzari, Elena Pezzolo, et al.
International Journal of Cancer|September 30, 2017
Sentinel lymph node biopsy versus observation in thick melanoma: A multicenter propensity score matching studyAram Boada, Antonio Tejera-Vaquerizo, Simone Ribero, et al.
Antibodies (Basel, Switzerland)|September 22, 2025
Safety and Effectiveness of Dupilumab in Atopic Dermatitis Patients with Hematologic Comorbidities: A Multicenter, Retrospective StudyLuca Bettolini, Stefano Bighetti, Silvia Mariel Ferrucci, et al.
Journal of Clinical Medicine|March 27, 2025
Effectiveness of Tralokinumab Across Atopic Dermatitis PhenotypesFrancesca Barei, Paolo Calzari, Elena Pezzolo, et al.
Frontiers in Public Health|September 2, 2024
Assessing a measure for Quality of Life in patients with severe Alopecia Areata: a multicentric Italian studyGiacomo Caldarola, Giulia Raimondi, Tonia Samela, et al.
Dermatology and Therapy|February 19, 2026
Psychological Well-Being of Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab: 28-Week Interim Results from a Multicenter Observational Study in Italy Using the DASS-21 Questionnaire, the BLUE StudyEmanuele Trovato, Claudio Bonifati, Simone Ribero, et al.
Dermatology and Therapy|June 9, 2026
Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective StudyLuciano Ibba, Sara Di Giulio, Piergiorgio Malagoli, et al.
American Journal of Clinical Dermatology|February 24, 2025
Safety and Effectiveness of Upadacitinib in Patients with Moderate-to-Severe Atopic Dermatitis Who Smoke: a 2-Year Real-Life Multicenter StudyFrancesco Leo, Michela Ortoncelli, Ruggero Cascio Ingurgio, et al.
Dermatology and Therapy|March 17, 2026
Short-Term Effectiveness and Safety of Deucravacitinib in Psoriasis: A Multicenter Real-World Study with Scalp-Specific Outcomes-IL PSO (Italian Landscape Psoriasis)Luciano Ibba, Sara Di Giulio, Piergiorgio Malagoli, et al.
Dermatology and Therapy|January 6, 2026
Clinical Trial Eligibility in Atopic Dermatitis: Data from a Large Real-World International CohortJosé Miguel Alvarenga, Jensen Yeung, Vimal Prajapati, et al.
Pageof 27